Acuta Capital Partners, LLC Mereo Biopharma Group PLC Transaction History

Acuta Capital Partners, LLC

  • $40.2 Million
  • Q2 2025

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025
BUY
$2.25 - $3.76 $28,140 - $47,026
12,507 Added 1.6%
791,815 $1.78 Million
Q4 2024

Feb 14, 2025
SELL
$3.29 - $4.62 $1.58 Million - $2.22 Million
-481,392 Reduced 38.18%
779,308 $2.73 Million
Q3 2024

Nov 14, 2024
BUY
$3.45 - $4.87 $2.01 Million - $2.84 Million
583,700 Added 86.22%
1,260,700 $5.18 Million
Q2 2024

Aug 14, 2024
BUY
$2.58 - $4.25 $720,119 - $1.19 Million
279,116 Added 70.15%
677,000 $2.44 Million
Q1 2024

May 15, 2024
BUY
$2.3 - $4.05 $915,133 - $1.61 Million
397,884 New
397,884 $1.31 Million

Others Institutions Holding MREO

# of Institutions
97
Shares Held
98.2M
Call Options Held
2.28M
Put Options Held
761K
View Full List

About Mereo Biopharma Group plc

MREO Quotes by TradingView
  • Ticker MREO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,986,000
  • Market Cap $207M
  • Description
  • Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...
More about MREO
Track This Portfolio

Track Acuta Capital Partners, LLC Portfolio

Follow Acuta Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acuta Capital Partners, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email